SIM
FBRX icon

Spark Investment Management’s Forte Biosciences FBRX Stock Holding History

Spark Investment Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-53
Closed -$162K – 670
2018
Q4 		$162K Buy
+53
New +$228K 0.01% 523

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spark Investment Management's FBRX Position: Q1 2019 in Review

Spark Investment Management sold out of Forte Biosciences (FBRX) in Q1 2019, closing a stake of 53 shares — an estimated $162K sold.

Spark Investment Management first reported a position in FBRX in Q4 2018 and held it in 1 quarter. The position peaked at $162K in Q4 2018. 78 funds tracked by Wall St. Rank hold FBRX as of Q1 2019.

  • Spark Investment Management reported no remaining Forte Biosciences position as of Q1 2019 after selling out during the quarter.
  • Spark Investment Management sold 53 Forte Biosciences shares in Q1 2019, an estimated $162K.
  • Spark Investment Management first reported a position in Forte Biosciences in Q4 2018 and held it in 1 quarter.
  • Spark Investment Management's Forte Biosciences position peaked at $162K in Q4 2018.
  • 78 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2019.

Based on Spark Investment Management's 13F filing for Q1 2019, filed 7 May 2019.